Liquid biopsy: from discovery to clinical implementation.
作者信息
Alix-Panabières Catherine, Pantel Klaus
机构信息
Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.
CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRD, Montpellier, France.
出版信息
Mol Oncol. 2021 Jun;15(6):1617-1621. doi: 10.1002/1878-0261.12997.
Abstract
摘要
相似文献
1
Liquid biopsy: from discovery to clinical implementation.液体活检：从发现到临床应用。
Mol Oncol. 2021 Jun;15(6):1617-1621. doi: 10.1002/1878-0261.12997.
2
Tumor-educated platelets.肿瘤教育的血小板。
Blood. 2019 May 30;133(22):2359-2364. doi: 10.1182/blood-2018-12-852830. Epub 2019 Mar 4.
3
Refining Cancer Management Using Integrated Liquid Biopsy.利用整合液体活检改善癌症管理。
Theranostics. 2020 Jan 16;10(5):2374-2384. doi: 10.7150/thno.40677. eCollection 2020.
4
Applications of liquid biopsies for cancer.液体活检在癌症中的应用。
Sci Transl Med. 2019 Aug 28;11(507). doi: 10.1126/scitranslmed.aay1984.
5
Liquid biopsy for cancer diagnosis and screening - The promise and challenges.用于癌症诊断和筛查的液体活检——前景与挑战
Ann Clin Biochem. 2019 Jul;56(4):420-423. doi: 10.1177/0004563219837592. Epub 2019 Apr 11.
6
Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.胰腺导管腺癌的液体活检：循环肿瘤细胞和循环肿瘤 DNA 的现状。
Mol Oncol. 2019 Aug;13(8):1623-1650. doi: 10.1002/1878-0261.12537. Epub 2019 Jul 30.
7
Potential of circulating biomarkers in liquid biopsy diagnostics.循环生物标志物在液体活检诊断中的潜力。
Biotechniques. 2018 Oct;65(4):187-189. doi: 10.2144/btn-2018-0093.
8
Liquid biopsy in head and neck squamous cell carcinoma: Prognostic significance of circulating tumor cells and circulating tumor DNA. A systematic review.头颈部鳞状细胞癌的液体活检：循环肿瘤细胞和循环肿瘤DNA的预后意义。一项系统综述。
Oral Oncol. 2019 Oct;97:7-17. doi: 10.1016/j.oraloncology.2019.07.003. Epub 2019 Aug 1.
9
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?液体活检在卵巢癌中应用循环肿瘤 DNA 和细胞：是否已经准备好进入黄金时代？
Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11.
10
Liquid Biopsy in Solid Malignancy.实体恶性肿瘤中的液体活检
Genet Test Mol Biomarkers. 2019 Apr;23(4):284-296. doi: 10.1089/gtmb.2018.0237. Epub 2019 Mar 27.
引用本文的文献
1
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood.液体活检的新应用：外周血中循环生物标志物探索的综合方法
J Liq Biopsy. 2025 Jun 26;9:100307. doi: 10.1016/j.jlb.2025.100307. eCollection 2025 Sep.
2
Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.生物标志物驱动的骨转移治疗方法：从分子机制到临床应用
Biomedicines. 2025 May 10;13(5):1160. doi: 10.3390/biomedicines13051160.
3
Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: Unveiling resistance mechanisms with the CoDuCo in situ assay.前列腺癌中循环肿瘤细胞和肿瘤组织的高多重表征的先进单细胞和空间分析：通过CoDuCo原位检测揭示耐药机制。
Biomark Res. 2024 Nov 16;12(1):140. doi: 10.1186/s40364-024-00680-z.
4
The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.人类挥发物组分析技术在癌症诊断中的应用：非侵入性应用的过去、现在和未来。
Metabolomics. 2024 Oct 7;20(5):113. doi: 10.1007/s11306-024-02180-5.
5
Circulating Tumor DNA in Patients with Desmoid Fibromatosis during Active Surveillance.活跃监测期间患有硬纤维瘤病患者的循环肿瘤 DNA。
Ann Surg Oncol. 2024 Dec;31(13):9265-9271. doi: 10.1245/s10434-024-16147-2. Epub 2024 Sep 7.
6
Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.肝切除术后及热消融后肝细胞癌复发的管理：现状与未来展望
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):71-88. doi: 10.21037/hbsn-22-579. Epub 2023 Jun 19.
7
Downregulation of JAM3 occurs in cholangiocarcinoma by hypermethylation: A potential molecular marker for diagnosis and prognosis.JAM3 在胆管癌中因 hypermethylation 而下调：用于诊断和预后的潜在分子标志物。
J Cell Mol Med. 2024 Jan;28(2):e18038. doi: 10.1111/jcmm.18038. Epub 2023 Dec 20.
8
Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging.为脑肿瘤液体活检增添价值：影像学的作用。
Cancers (Basel). 2023 Oct 29;15(21):5198. doi: 10.3390/cancers15215198.
9
Immunotherapy through the Lens of Non-Small Cell Lung Cancer.从非小细胞肺癌视角看免疫疗法
Cancers (Basel). 2023 May 30;15(11):2996. doi: 10.3390/cancers15112996.
10
Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype.循环肿瘤细胞的力学生物学与生存策略：迈向侵袭性和转移表型的过程
Front Cell Dev Biol. 2023 May 5;11:1188499. doi: 10.3389/fcell.2023.1188499. eCollection 2023.
本文引用的文献
1
Photonic technologies for liquid biopsies: recent advances and open research challenges.用于液体活检的光子技术：最新进展与开放研究挑战
Laser Photon Rev. 2021 Jan;15(1). doi: 10.1002/lpor.202000255. Epub 2020 Dec 2.
2
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.循环肿瘤 DNA 突变作为一种液体活检在肺癌检测和治疗中的应用。
Mol Oncol. 2021 Jun;15(6):1667-1682. doi: 10.1002/1878-0261.12983. Epub 2021 May 26.
3
Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.ctDNA 中表观遗传标记的检测及其相关性：最新进展与未来展望。
Mol Oncol. 2021 Jun;15(6):1683-1700. doi: 10.1002/1878-0261.12978. Epub 2021 May 14.
4
Liquid Biopsy: From Discovery to Clinical Application.液体活检：从发现到临床应用。
Cancer Discov. 2021 Apr;11(4):858-873. doi: 10.1158/2159-8290.CD-20-1311.
5
Circulating tumor cell profiling for precision oncology.循环肿瘤细胞分析在精准肿瘤学中的应用。
Mol Oncol. 2021 Jun;15(6):1622-1646. doi: 10.1002/1878-0261.12901. Epub 2021 Feb 1.
6
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.错配修复缺陷肿瘤细胞中的DNA传感对于抗肿瘤免疫至关重要。
Cancer Cell. 2021 Jan 11;39(1):96-108.e6. doi: 10.1016/j.ccell.2020.11.006. Epub 2020 Dec 17.
7
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology.下一代液体活检：肿瘤学中的数据分析科学。
Trends Cancer. 2021 Apr;7(4):283-292. doi: 10.1016/j.trecan.2020.11.001. Epub 2020 Dec 13.
8
Clinical utility of circulating tumor cells: an update.循环肿瘤细胞的临床应用：更新。
Mol Oncol. 2021 Jun;15(6):1647-1666. doi: 10.1002/1878-0261.12869. Epub 2020 Dec 25.
9
Circulating platelets as liquid biopsy sources for cancer detection.循环血小板作为癌症检测的液体活检源。
Mol Oncol. 2021 Jun;15(6):1727-1743. doi: 10.1002/1878-0261.12859. Epub 2020 Dec 14.
10
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.循环肿瘤细胞计数驱动与临床医生驱动一线治疗选择在激素受体阳性、ERBB2 阴性转移性乳腺癌中的疗效：STIC CTC 随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):34-41. doi: 10.1001/jamaoncol.2020.5660.
Zotero 插件